Dr. Jacob M. Sands, MD

Medicare patients and services

Medicare patients, 2024

159

Services billed

476

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 18 companies reported 82 payments worth $110,881 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 17 industry-funded studies in 2025, from 7 companies. The companies reported $3,211,729 in research payments for these studies, mostly to the institutions running them.

• First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
  Daiichi Sankyo Inc. · Active, not recruiting · NCT03401385
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
  Eli Lilly and Company · Active, not recruiting · NCT03157128
• A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
  Daiichi Sankyo Inc. · Active, not recruiting · NCT06244485
• A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
  Amgen Inc.
• An observational study to evaluate the incidence of lambert-eaton myasthenic syndrome (lems) in subjects diagnosed with small cell lung cancer (sclc)
  Catalyst Pharmaceuticals, Inc.
• A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
  Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04420884
• A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
  Amgen Inc.
• ALI-4201
  Puma Biotechnology, Inc.
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
  Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  Daiichi Sankyo Inc. · Recruiting · NCT06203210

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Burlington

• Edward C. Dow, MD
• Maria Galkin, MD
• Paul J. Hesketh, MD
• Francis Nugent, M.D.
• Paola F. Rode, M.D.
• David Steinberg, MD
• Lata C. Thatai, MD
• Douglas D. Tisdale, MD